ARTICLE | Management Tracks
Min Liu succeeds Yiping Li as CEO of JW
Plus: John Chin to retire as CBO from Antengene, and updates from ADARx, bit bio and Santhera
July 31, 2024 11:33 PM UTC
JW Therapeutics Co. Ltd. (HKEX:2126) appointed Min Liu as CEO and executive director. Liu succeeds Yiping Li, who resigned as CEO for personal reasons and has become a non-executive director, while remaining interim chairman. Liu was chief commercial officer of Innovent Biologics Inc. (HKEX:1801) for four years until September 2022, before which he was at Roche (SIX:ROG; OTCQX:RHHBY) in China. JW also disclosed the resignation of non-executive directors Ann Lee and Krishnan Viswanadhan.
John Chin will retire as executive director and CBO of Antengene Corp. Ltd. (HKEX:6996) on Aug. 1. Chin, who joined in 2020, will remain a consultant to the company...